Another interesting research avenue regards how IDH inhibitor treatment may modify the function of some molecular pathways, such as JAK/STAT3, with several studies reporting that STAT3 levels in the TME may be associated with primary and secondary resistance to ICIs in solid tumors, including non-small cell lung cancer [26,27]. This evidence concerns the gene STAT3 and non-small cell lung carcinoma.